Evaluation of Financial and Non-financial Conflicts of Interest and Quality of Evidence underlying Psoriatic Arthritis Clinical Practice Guidelines-Analysis of Personal Payments from Pharmaceutical Companies and Authors' Self-citation Rate in Japan and the United States

Hanano Mamada, Anju Murayama, Sae Kamamoto, Yudai Kaneda, Makoto Yoshida, Sota Sugiura, Erika Yamashita, Eiji Kusumi, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto, Matt Vassar, Piotr Ozieranski, Akihiko Ozaki

OAI: oai:purehost.bath.ac.uk:publications/3d5f3bd5-faf0-4150-add3-2db264742035 • DOI: https://doi.org/10.1002/acr.25032

OBJECTIVE: To assess financial conflict of interest (FCOI) and non-financial conflicts of interest (NFCOI) among psoriatic arthritis clinical practice guideline (PsACPG) authors in Japan and US, and to evaluate the quality of evidence and strength of recommendations of PsACPG.

METHODS: We performed a retrospective analysis using payment data from major Japanese pharmaceutical companies and the US Open Payments Database from 2016 to 2018. All authors of PsACPG issued by Japanese Dermatological Association (JDAPsACPG) and American College of Rheumatology (ACRPsACPG) were included.

RESULTS: Of 23 CPG authors in Japan, 21 (91.3%) received at least one payment, with the combined total of $3,335,413 between 2016 and 2018. Regarding 25 US authors, 21 (84.0%) received at least one payment, with the combined total of $4,081,629 during the same period. The 3-year combined average payment per author was $145,018 (standard division [SD]: $114,302) in Japan and $162,825 (SD: $259,670) in US. 18 (78.3%) JDAPsACPG and 12 (48.0%) ACRPsACPG authors had undisclosed FCOI worth $474,663 and $218,501, respectively. The percentage of citations with at least one CPG author relative to total citations were 3.4% in Japan and 33.6% in US. 71.4% and 88.8% of recommendations for psoriatic arthritis in JDA and ACR were supported by low or very low quality of evidence.

CONCLUSION: More rigorous cross-checking of information disclosed by pharmaceutical companies and self-reported by physicians, and more stringent and transparent COI policies are necessary.